Diamyd(R) Study Published in Prestigious New England Journal o...( STOCKHOLM October 9 /- Diamyd Med...),Health

STOCKHOLM, October 9 /PRNewswire-FirstCall/ -- Diamyd Medical reports that the world's most influential medical journal, the New England Journal of Medicine, has published an article with results from the company's study of the Diamyd(R) diabetes vaccine for type 1 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 )

The article is now available on the journal's web site (http://www.nejm.org) and will be in print on October 30. It presents the results of the concluded Phase II study of the Diamyd(R) diabetes vaccine. The article provides detailed information about the study, which showed that Diamyd(R) helped children and adolescents with type 1 diabetes, who participated in the study, retain the ability to produce their own insulin without causing any serious side effects.

"The results show that treatment with Diamyd(R) clearly has a positive effect on the course of type 1 diabetes, the most common serious, chronic disease among children," says Professor Johnny Ludvigsson at Linkoping University Hospital, who is first author of the article and responsible for the study.

The New England Journal of Medicine is the world's oldest and most influential medical journal, recognized for the high scientific standards of its content. Every year they receive more than 5,000 scientific articles from around the world, but only a fraction of them are selected for publication. Articles published in the journal are often noted over the entire world and reach many researchers, doctors and other interested parties.

"This is the ultimate scientific validation of the study results," says Peter Zerhouni, Director of Business Development at Diamyd and co-author of the article. "The material was reviewed and scrutinized several times by experts from different areas before publication."

"That our
'/>"/>